
Welcome to Novo Nordisk in the U.S. | Novo Nordisk U.S. Website
Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.
Novo Nordisk
Dec 18, 2025 · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other …
Novo Nordisk - Wikipedia
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, [3] with production facilities in nine countries and affiliates or offices in five.
Nordisk Outdoor | Premium Quality Equipment & Tents
Nordisk Company equipment for your outdoor lifestyle. Find premium equipment from our wide range of tents, sleeping bags and accessories for outdoors adventures.
Novo Nordisk Patient Assistance Program (PAP) | NovoCare®
Learn about Novo Nordisk's Patient Assistance Program (PAP), which provides medication at no cost to eligible individuals living with diabetes.
Novo Nordisk beyond weight loss has investors wary, scientists
3 days ago · Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say …
Novo Nordisk A/S | History, Structure, Products & Facts
Novo Nordisk A/S is an international pharmaceutical research, development, and manufacturing corporation established in 1989 through the merger of competing Danish companies Nordisk …
Who we are - Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes …
Novo Nordisk Shares Jump After US Approves Wegovy Pill
Dec 23 (Reuters) - Novo Nordisk shares jumped 10% on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill, giving the Danish drugmaker a competitive edge …
Novo Nordisk just pulled off something nobody saw coming
5 days ago · Novo Nordisk's new development could increase access for U.S. patients.